Navigation Links
Savient Pharmaceuticals to Present at the Bank of America Merrill Lynch 2012 Health Care Conference
Date:5/3/2012

EAST BRUNSWICK, N.J., May 3, 2012 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced that the Company will present at the Bank of America Merrill Lynch 2012 Health Care Conference on Thursday, May 17, 2012, at 11:20 a.m. PT.

A live webcast of the presentation can be accessed through the investor relations section of the Company's website at www.savient.com. Following the live presentation, a replay of the webcast will be available on the Company's website for 30 days.

ABOUT SAVIENT PHARMACEUTICALS, INC.Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA® (pegloticase) for the treatment of chronic gout in adult patients refractory to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA and its uses from Duke University ("Duke") and Mountain View Pharmaceuticals, Inc. ("MVP").  Duke developed the recombinant uricase enzyme and MVP developed the PEGylation technology used in the manufacture of KRYSTEXXA. MVP and Duke have been granted U.S. and foreign patents disclosing and claiming the licensed technology and, in addition, Savient owns or co-owns U.S. and foreign patents and patent applications, which collectively form a broad portfolio of patents covering the composition, manufacture and methods of use and administration of KRYSTEXXA.  Savient also manufactures and supplies Oxandrin® (oxandrolone tablets, USP) CIII in the U.S. For more information, please visit the Company's website at www.savient.com.

SVNT – GContact:Mary Coleman

Carney Noensie Savient Pharmaceuticals, Inc.

Burns McClellan  information@savient.com

cnoensie@burnsmc.com (732) 418-9300

(212) 213-0006 


'/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
2. Savient Pharmaceuticals to Present at the Imperial Capital Healthcare Investor Forum
3. Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2011 Results
4. Savient Pharmaceuticals to Present at the Cowen and Company 32nd Annual Health Care Conference
5. Savient Pharmaceuticals to Present at the Citi 2012 Global Health Care Conference
6. Savient Pharmaceuticals Appoints David Y. Norton Interim Chief Executive Officer
7. Savient Pharmaceuticals Appoints Experienced Pharmaceutical Executive, David Veitch as President of Savient Europe
8. Savient Pharmaceuticals Announces Permanent J-Code Assigned for KRYSTEXXA®
9. Savient Pharmaceuticals to Present at the Noble Financial Capital Markets Eighth Annual Equity Conference
10. Savient Pharmaceuticals Announces New Data Surrounding KRYSTEXXA® and the Impact of Refractory Chronic Gout at the American College of Rheumatology Meeting
11. Savient Pharmaceuticals Reports Third Quarter 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... Jan. 19, 2017 ViewRay, Inc. (Nasdaq: VRAY) announced ... institution supporting research in Germany , ... treatments at the University Clinic Heidelberg as part of ... MRIdian Linac program will be headed by Medical Director ... radiation oncology at the German Cancer Research Center (DKFZ), ...
(Date:1/19/2017)... , January 19, 2017 ... Option to Address Motor Symptoms and Motor Complications ... ...      (Logo: http://photos.prnewswire.com/prnh/20151014/276718LOGO) ... , European Neurological Review,2016;11(Suppl. 2): 2-15, http://www.touchneurology.com/articles/safinamide-new-therapeutic-option-address-motor-symptoms-and-motor-complications-mid-late ...
(Date:1/19/2017)... 18, 2017  ViewRay, Inc. (Nasdaq: ... only clinical MRI-guided radiation therapy system, announced today that ... $26.1 million through a private placement of its ... the financing and was joined by certain of ... Kearny Venture Partners, and an additional new institutional ...
Breaking Medicine Technology:
(Date:1/20/2017)... (PRWEB) , ... January 20, 2017 , ... Source Vitál ... and 100 percent pure essential oils, announced the company had a successful visit to ... The annual ECRM event gives companies that work in the nutritional, sports and health ...
(Date:1/20/2017)... Florida (PRWEB) , ... January 20, 2017 , ... Lice ... head lice cases in families with school-aged children since the holiday season. , ... the holidays with their families, sharing hugs and taking photos, which is the head-to-head ...
(Date:1/20/2017)... raton florida (PRWEB) , ... January 20, 2017 , ... ... at the Dana Farber Cancer Institute. For Betsy, the clinical trial has been ... her cancer has not worsened. , Betsy Brauser was diagnosed with ovarian cancer ...
(Date:1/20/2017)... ... 2017 , ... “Mary Magdalene: Grace is Greater than Sin”: a unique ... Jesus Christ firsthand. “Mary Magdalene: Grace is Greater than Sin” is the creation of ... interacting with countless women who had little knowledge of the female characters portrayed in ...
(Date:1/20/2017)... ... ... You”: a fine examination of how God handles sin, including how to let go ... Miller, who, for over ten long years has been waiting to release this powerful insight ... he has been serving the Lord for over twenty years, and he has been preaching ...
Breaking Medicine News(10 mins):